<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03416166</url>
  </required_header>
  <id_info>
    <org_study_id>2016-01753</org_study_id>
    <nct_id>NCT03416166</nct_id>
  </id_info>
  <brief_title>International Multisite Transcatheter Tricuspid Valve Therapies Registry</brief_title>
  <acronym>TriValve</acronym>
  <official_title>International Multisite Transcatheter Tricuspid Valve Therapies Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For a long time, tricuspid valve disease has been considered as less important than&#xD;
      left-sided valvular heart disease. If treated in an advanced stage and simultaneously with&#xD;
      other cardiac diseases, it is associated with significant morbidity and mortality. Hence,&#xD;
      physicians tend to refer patients more aggressively to surgery (1).&#xD;
&#xD;
      Transcatheter procedures are an attractive alternative in high-risk patients. The field of&#xD;
      transcatheter tricuspid devices has rapidly advanced over the last few years (2). Limited&#xD;
      knowledge is available regarding the epidemiologic and anatomical settings in which these&#xD;
      therapies are preferentially applied.&#xD;
&#xD;
      The main purpose of this registry is the collection of baseline clinical and anatomical data&#xD;
      of the patients treated with transcatheter tricuspid valve therapies, and their outcomes,&#xD;
      whenever feasible. Apart from more knowledge regarding the current status in this field, the&#xD;
      results could also help the establishment of guidelines with respect to the choice of the&#xD;
      transcatheter device selected and to understand which therapy can provide the better outcome&#xD;
      in the different anatomies. Moreover, this study will provide important information about the&#xD;
      epidemiology of severe tricuspid regurgitation, which is at the moment an undertreated&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2016</start_date>
  <completion_date type="Anticipated">November 1, 2026</completion_date>
  <primary_completion_date type="Actual">May 15, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Cardiovascular Death</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NYHA Class</measure>
    <time_frame>30 days, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TR Reduction</measure>
    <time_frame>30 days, 1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">269</enrollment>
  <condition>Severe Tricuspid Regurgitation</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Tricuspid Intervention</intervention_name>
    <description>Any available transcatheter tricuspid valve intervention</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe symptomatic tricuspid regurgitation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All the patients undergoing transcatheter tricuspid valve intervention.&#xD;
&#xD;
        General inclusion criteria:&#xD;
&#xD;
          -  Minimal age: 18 years&#xD;
&#xD;
          -  Patient is able to give written informed consent to the procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not fulfilling the indications for transcatheter tricuspid intervention&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Maurizio Taramasso, MD, PhD</last_name>
    <phone>0041442553728</phone>
    <email>maurizio.taramasso@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>ZÃ¼rich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Taramasso, MD, PhD</last_name>
      <phone>0041442553728</phone>
      <email>maurizio.taramasso@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2018</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tricuspid Valve</keyword>
  <keyword>tricuspid regurgitation</keyword>
  <keyword>transcatheter tricuspid regurgitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

